Total Payments
$30,357
2024 Payments
$99.75
Companies
12
Transactions
79
Payment Breakdown by Category
Consulting$20,800 (68.5%)
Travel$8,004 (26.4%)
Food & Beverage$1,525 (5.0%)
Education$28.48 (0.1%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $20,800 | 5 | 68.5% |
| Travel and Lodging | $8,004 | 7 | 26.4% |
| Food and Beverage | $1,525 | 66 | 5.0% |
| Education | $28.48 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $29,075 | 15 | $0 (2023) |
| ViiV Healthcare Company | $472.96 | 24 | $0 (2022) |
| Gilead Sciences, Inc. | $330.73 | 15 | $0 (2020) |
| Janssen Biotech, Inc. | $222.58 | 13 | $0 (2023) |
| Astellas Pharma US Inc | $52.79 | 2 | $0 (2024) |
| Napo Pharmaceuticals Inc | $46.78 | 2 | $0 (2024) |
| TETRAPHASE PHARMACEUTICALS, INC. | $45.31 | 2 | $0 (2019) |
| Janssen Pharmaceuticals, Inc | $28.48 | 1 | $0 (2023) |
| The Medicines Company | $25.33 | 2 | $0 (2017) |
| Merck Sharp & Dohme LLC | $22.63 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $99.75 | 4 | Napo Pharmaceuticals Inc ($32.28) |
| 2023 | $25,235 | 15 | GlaxoSmithKline, LLC. ($25,175) |
| 2022 | $3,921 | 3 | GlaxoSmithKline, LLC. ($3,900) |
| 2020 | $48.91 | 2 | Gilead Sciences, Inc. ($24.76) |
| 2019 | $349.83 | 17 | ViiV Healthcare Company ($153.03) |
| 2018 | $245.95 | 13 | Gilead Sciences, Inc. ($103.99) |
| 2017 | $456.85 | 25 | ViiV Healthcare Company ($197.01) |
All Payment Transactions
79 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/04/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $30.10 | General |
| Category: Infectious Diseases | ||||||
| 07/18/2024 | Merck Sharp & Dohme LLC | PIFELTRO (Drug), DELSTRIGO | Food and Beverage | In-kind items and services | $22.63 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 06/04/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $14.74 | General |
| 05/16/2024 | Napo Pharmaceuticals Inc | Mytesi (Drug) | Food and Beverage | Cash or cash equivalent | $32.28 | General |
| Category: Infectious Disease | ||||||
| 10/12/2023 | Janssen Pharmaceuticals, Inc | — | Education | In-kind items and services | $28.48 | General |
| 09/14/2023 | GlaxoSmithKline, LLC. | SHINGRIX (Biological) | Consulting Fee | Cash or cash equivalent | $3,575.00 | General |
| Category: VACCINES | ||||||
| 09/08/2023 | GlaxoSmithKline, LLC. | SHINGRIX (Biological) | Travel and Lodging | Cash or cash equivalent | $1,349.09 | General |
| Category: VACCINES | ||||||
| 09/08/2023 | GlaxoSmithKline, LLC. | SHINGRIX (Biological) | Travel and Lodging | Cash or cash equivalent | $578.46 | General |
| Category: VACCINES | ||||||
| 09/08/2023 | GlaxoSmithKline, LLC. | SHINGRIX (Biological) | Food and Beverage | Cash or cash equivalent | $56.43 | General |
| Category: VACCINES | ||||||
| 06/30/2023 | GlaxoSmithKline, LLC. | SHINGRIX (Biological) | Consulting Fee | Cash or cash equivalent | $1,625.00 | General |
| Category: VACCINES | ||||||
| 06/27/2023 | GlaxoSmithKline, LLC. | SHINGRIX (Biological) | Travel and Lodging | Cash or cash equivalent | $22.27 | General |
| Category: VACCINES | ||||||
| 04/12/2023 | Janssen Biotech, Inc. | SYMTUZA (Drug) | Food and Beverage | In-kind items and services | $31.19 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 03/14/2023 | GlaxoSmithKline, LLC. | SHINGRIX (Biological) | Travel and Lodging | Cash or cash equivalent | $3,815.51 | General |
| Category: VACCINES | ||||||
| 03/14/2023 | GlaxoSmithKline, LLC. | SHINGRIX (Biological) | Travel and Lodging | Cash or cash equivalent | $523.60 | General |
| Category: VACCINES | ||||||
| 03/14/2023 | GlaxoSmithKline, LLC. | SHINGRIX (Biological) | Food and Beverage | Cash or cash equivalent | $96.31 | General |
| Category: VACCINES | ||||||
| 01/31/2023 | GlaxoSmithKline, LLC. | SHINGRIX (Biological) | Travel and Lodging | Cash or cash equivalent | $1,136.15 | General |
| Category: VACCINES | ||||||
| 01/31/2023 | GlaxoSmithKline, LLC. | SHINGRIX (Biological) | Travel and Lodging | Cash or cash equivalent | $578.74 | General |
| Category: VACCINES | ||||||
| 01/31/2023 | GlaxoSmithKline, LLC. | SHINGRIX (Biological) | Food and Beverage | Cash or cash equivalent | $118.59 | General |
| Category: VACCINES | ||||||
| 01/17/2023 | GlaxoSmithKline, LLC. | SHINGRIX (Biological) | Consulting Fee | Cash or cash equivalent | $11,700.00 | General |
| Category: VACCINES | ||||||
| 10/04/2022 | GlaxoSmithKline, LLC. | SHINGRIX (Biological) | Consulting Fee | Cash or cash equivalent | $1,950.00 | General |
| Category: VACCINES | ||||||
| 05/24/2022 | GlaxoSmithKline, LLC. | SHINGRIX (Biological) | Consulting Fee | Cash or cash equivalent | $1,950.00 | General |
| Category: VACCINES | ||||||
| 03/14/2022 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $21.20 | General |
| Category: HIV | ||||||
| 02/26/2020 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.76 | General |
| 02/26/2020 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $24.15 | General |
| Category: HIV | ||||||
| 12/10/2019 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $15.04 | General |
| Category: HIV | ||||||
About Dr. Katya Corado, M.D
Dr. Katya Corado, M.D is a Internal Medicine healthcare provider based in Long Beach, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/09/2007. The National Provider Identifier (NPI) number assigned to this provider is 1013109461.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Katya Corado, M.D has received a total of $30,357 in payments from pharmaceutical and medical device companies, with $99.75 received in 2024. These payments were reported across 79 transactions from 12 companies. The most common payment nature is "Consulting Fee" ($20,800).
Ad
Practice Information
- Specialty Internal Medicine
- Location Long Beach, CA
- Active Since 08/09/2007
- Last Updated 11/10/2014
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1013109461
Products in Payments
- SHINGRIX (Biological) $29,075
- TRIUMEQ (Drug) $155.31
- DOVATO (Drug) $154.14
- PREZCOBIX (Drug) $134.39
- Symtuza (Drug) $57.00
- Mytesi (Drug) $46.78
- Xerava (Drug) $45.31
- JULUCA (Drug) $36.54
- SYMTUZA (Drug) $31.19
- Cresemba (Drug) $30.10
- TIVICAY (Drug) $23.97
- CRESEMBA (Drug) $22.69
- PIFELTRO (Drug) $22.63
- CABENUVA (Biological) $21.20
- Baxdela (Drug) $19.83
- MINOCIN IV (Drug) $14.67
- ORBACTIV (Drug) $10.66
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Long Beach
Jennifer Connelly, D.o, D.O
Internal Medicine — Payments: $275,877
Internal Medicine $275,877
Dr. Mark Lee, Md, MD
Internal Medicine — Payments: $142,649
Internal Medicine $142,649
Dr. Mark Leibowitz, M.d, M.D
Internal Medicine — Payments: $103,211
Internal Medicine $103,211
Dr. Steven Appleby, Md, MD
Internal Medicine — Payments: $101,644
Internal Medicine $101,644
Dr. Milan Sheth, Md, MD
Internal Medicine — Payments: $71,682
Internal Medicine $71,682
Dr. Diane Chau, Md, MD
Internal Medicine — Payments: $26,560
Internal Medicine $26,560